HIV protease inhibitors

Details HIV protease inhibitors HIV protease inhibitors

1993-07-26

1995-08-01

Warden, Jill

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

4 to 5 amino acid residues in defined sequence

530331, 540492, 540526, 540531, A61K 3800, C07K 500, C07K 700, C07K 1700

Patent

active

054381185

DESCRIPTION:

BRIEF SUMMARY
The present invention is directed to compounds containing chemical mimics which constrain peptide conformation. These compounds are inhibitors of the human immunodeficiency virus (HIV) protease and are useful for treating HIV infection and for treating acquired immune deficiency syndrome (AIDS).
The compounds of this invention are also renin inhibitors and thus are useful in treating hypertension.
This invention further relates to pharmaceutical compositions which comprise a compound of this invention and a pharmaceutically acceptable carrier.
Also, this invention relates to methods of treating AIDS and to methods of preventing and/or treating infection by HIV. These methods comprise administering to a mammal in need thereof an effective amount of a compound of this invention.


BACKGROUND OF THE INVENTION

The retrovirus, HIV which is a virus within the family of Retroviridae, is the etiological agent of AIDS and AIDS-related complexes. Viral replication occurs only within host cells and is dependent upon host cellular functions. The production of functional viral proteins is critical to this replication. Protein synthesis is accomplished by translation of the open reading frames into polyprotein constructs, corresponding to the gag, pol, and env reading frames, which are processed, at least in part, by a viral protease into the functional proteins. The proteolytic activity provided by the viral protease in processing the polyproteins cannot be provided by the host and is essential to the life cycle of the retrovirus. Methods to express retroviral proteases in E. coli have been disclosed by Debouck, et al., Proc. Natl. Acad. Sci. USA, 8903-06 9 (1987) and Graves, et al., Proc. Natl. Acad. Sci. USA, 85, 2449-53 (1988) for the HIV-1 virus. In fact, it has been demonstrated that retroviruses which lack the protease, or contain a mutated form of it, lack infectivity. See Katoh et al., Virology, 145, 280-92 (1985), Crawford et al., J. Virol, 53, 899-907 (1985) and Debouck et al., Proc. Natl. Acad. Sci. USA, 84, 8903-6 (1987). Inhibition of retroviral proteases, such as HIV protease, presents a method of therapy for retroviral diseases, such as AIDS. There exists a need for compounds which inhibit retroviral protease activity for pharmaceutical use to provide therapy for diseases which are caused by such retroviruses.
EP-A 352,000 and EP-A 337,714, which are incorporated herein by reference, disclose peptide-like compounds which inhibit retroviral proteases. Neither of these references disclose compounds having the constrained peptide backbone conformation which is the significant feature of the inhibitor compounds of the present invention.
Gamma turn mimics have been reported in the following-publications: Huffman et al., Peptides, Chemistry and Biology, Proceedings of the Tenth American Peptide Symposium, (Marshall, G., ed.), ESCOM, Luden, 1988, pp. 105-8. Huffman et al., Synthetic Peptides: Approaches to Biological Problems. UCLA Symposium on Molecular and Cellular Biology, Vol. 86 (Tam, J. and Kaiser, E., eds.) Alan R. Liss, Inc., New York, 1988. Huffman et al., 10th American Peptide Symposium, Abstract, May 1987. Callahan et al., 30th Organic Symposium, Abstract, June 1987. Lack of significant biological activity was reported.
X-ray crystal structures of certain aspartic acid-based enzyme inhibitors bound to the active sites of the enzymes reveal that a C-7 or gamma turn conformation about the amino acid in the P1 site is compatible with the pharmacophore for inhibition. We have found that compounds containing synthetic mimics, which constrain the peptide backbone conformation, are inhibitors of HIV protease. They are also inhibitors of renin.


DESCRIPTION OF THE INVENTION

The compounds of this invention are illustrated by the following Formula I: ##STR1## in which: D is A' or ##STR2## X is ##STR3## V and W are each independently N or C; one of -- indicated bonds is a double bond and the other is a single bond or, when W is N, -- both are single bonds; (CH.sub.2).sub.n CONHR', (CH.sub.2).sub.n OR' or (CH

REFERENCES:
Huffman et al. Proc. of the 10th American Peptide Symposium, issued 5/87 pp. 105-108.
ASM News 7/90, vol. 56 p. 368.
Blumenstein et al. Biochem Biophys. Res. Comm. vol. 163 p. 980 (1989).
Bolis et al. J. Med Chem. vol. 30 p. 1730 (1987).
Burger, Med. Chem. (1960) p. 565.

Affiliated with

Also associated with

Rating

HIV protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-734341